English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, we have analyzed total 56 persons. Where 26 people are with Parkinson’s Disease (PD) and 30 people are control group. The genes alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase2 (LRRK2 or dardarin), PTEN-Induced Putative Kinase1 (PINK1), DJ-1 and ATP13A2 analyzed in terms of genetic mutations made. In this study, people who have genetic mutations were targeted, with nervous disorders, Parkinson’s Disease (PD). In fact, of all people with Parkinson’s Disease (PD), 160 Parkinson’s Disease (PD) had a genetic mutation in the genes Alpha-Synuclein (SNCA), parkin (PRKN), Leucine-Rich Repeat Kinase2 (LRRK2 or dardarin) And 107 Parkinson’s Disease (PD) had a genetic mutation in PTEN-Induced Putative Kinase1 (PINK1), DJ-1 and ATP13A2 respectively. Any genetic mutations in the target genes control group, did not show.

international journal of genomics and data mining

Assessment of Genetic Mutations in Genes Alpha-Synuclein (SNCA), Parkin (PRKN), Leucine-Rich Repeat Kinase2 (LRRK2 or Dardarin), PTEN-Induced Putative Kinase 1 (PINK1), DJ-1 and ATP13A2 Induced Parkinson's Disease (PD) in Patients Tabriz, IRAN